An insight into the functional alterations in the gut microbiome of healthy adults in response to a multi-strain probiotic intake: a single arm open label trial.
gut microbiome
healthy adults
metagenomics
microbiome
probiotics
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
06
2023
accepted:
11
09
2023
medline:
23
10
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
Probiotic supplements, by definition, provide a benefit to the host, but few studies have investigated the effect of probiotic supplements in healthy adult populations. The present, single arm, open label clinical trial, evaluated compositional and functional changes in the fecal microbiome of healthy adults after supplementation with a 14-strain probiotic. We analysed the effect of a 14-strain probiotic blend ( In healthy adult participants, no significant changes to the overall alpha- or beta-diversity was observed after 8 weeks of multi-strain probiotic supplementation. However, in a simplified model that considered only time and individual differences, significant decreases (p < 0.05) in family In healthy young adults, overall alpha- and beta-diversity did not change in response to probiotic intake even though modest compositional changes at the family and genus level were observed. However, at functional level, results identified changes in gene abundance for several functional pathways.
Sections du résumé
Background
Probiotic supplements, by definition, provide a benefit to the host, but few studies have investigated the effect of probiotic supplements in healthy adult populations.
Purpose
The present, single arm, open label clinical trial, evaluated compositional and functional changes in the fecal microbiome of healthy adults after supplementation with a 14-strain probiotic.
Methods
We analysed the effect of a 14-strain probiotic blend (
Results
In healthy adult participants, no significant changes to the overall alpha- or beta-diversity was observed after 8 weeks of multi-strain probiotic supplementation. However, in a simplified model that considered only time and individual differences, significant decreases (p < 0.05) in family
Conclusion
In healthy young adults, overall alpha- and beta-diversity did not change in response to probiotic intake even though modest compositional changes at the family and genus level were observed. However, at functional level, results identified changes in gene abundance for several functional pathways.
Identifiants
pubmed: 37841999
doi: 10.3389/fcimb.2023.1240267
pmc: PMC10570534
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1240267Informations de copyright
Copyright © 2023 Rodenes-Gavidia, Lamelas, Bloor, Hobson, Treadway, Haworth, Vijayakumar, Naghibi, Day and Chenoll.
Déclaration de conflit d'intérêts
Authors VV, RD, MN, EC, AR-G, and AL were employed by the company ADM. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from ADM Protexin. ADM Protexin had the following involvement in the study: study design.
Références
FEMS Microbiol Rev. 2004 Oct;28(4):405-40
pubmed: 15374659
Bioinformatics. 2015 May 15;31(10):1674-6
pubmed: 25609793
Nature. 2015 Dec 10;528(7581):262-266
pubmed: 26633628
Nutrients. 2017 Sep 15;9(9):
pubmed: 28914794
Nutrients. 2019 Apr 27;11(5):
pubmed: 31035617
Nature. 2012 Oct 4;490(7418):55-60
pubmed: 23023125
Am J Health Syst Pharm. 2010 Mar 15;67(6):449-58
pubmed: 20208051
J Mol Biol. 2016 Feb 22;428(4):726-731
pubmed: 26585406
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14
pubmed: 24912386
Expert Rev Anti Infect Ther. 2019 Sep;17(9):733-740
pubmed: 31516055
Nat Commun. 2015 Mar 11;6:6528
pubmed: 25758642
Microbiome. 2019 Jun 3;7(1):84
pubmed: 31159881
Psychol Med. 2023 Jun;53(8):3437-3447
pubmed: 35129111
PLoS One. 2017 Oct 26;12(10):e0185056
pubmed: 29073143
Cephalalgia. 2019 Jun;39(7):841-853
pubmed: 30621517
Biomedicines. 2021 Sep 28;9(10):
pubmed: 34680457
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Gastroenterology. 2021 Jan;160(2):524-537
pubmed: 33253681
Microorganisms. 2019 Jan 10;7(1):
pubmed: 30634578
BMC Gastroenterol. 2018 May 25;18(1):71
pubmed: 29801486
Gut. 2017 Jan;66(1):70-78
pubmed: 26408641
Indian J Med Microbiol. 2015 Feb;33 Suppl:2-10
pubmed: 25657150
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Am J Gastroenterol. 2017 May;112(5):775-784
pubmed: 28323273
Nat Commun. 2015 Apr 28;6:6342
pubmed: 25919227
Pharmaceuticals (Basel). 2014 Oct 10;7(10):999-1007
pubmed: 25310351
Br J Pharmacol. 2017 Jun;174(11):1426-1449
pubmed: 27696378
Nat Biotechnol. 2023 Feb 23;:
pubmed: 36823356
Mediators Inflamm. 2018 Dec 9;2018:2037838
pubmed: 30622429
Genome Med. 2016 May 10;8(1):52
pubmed: 27159972
BMC Bioinformatics. 2010 Mar 08;11:119
pubmed: 20211023
PLoS Pathog. 2010 Sep 09;6(9):e1001097
pubmed: 20844578
Microbiome. 2019 Sep 13;7(1):130
pubmed: 31519223
Gut. 2022 May;71(5):1020-1032
pubmed: 35105664